Cardiology AdvisorInclisiran Lowers LDL-C in Patients with Hyperlipidemia

Inclisiran has emerged as a novel lipid-lowering therapy targeting PCSK9 synthesis through RNA interference. This meta-analysis evaluated the consistency of LDL-C reduction and safety across randomized trials involving patients with hyperlipidemia, ASCVD, and ASCVD-risk equivalents.

Clinical Considerations

• Analysis included 9 randomized trials and 6,355 patients with hyperlipidemia.
• Inclisiran reduced LDL-C by a mean 48.8% versus placebo across studies.
• Absolute LDL-C reduction averaged 58.2 mg/dL compared with placebo.
• No significant differences in treatment-emergent or treatment-related adverse events were observed.

Practice Applications

• Consider inclisiran within contemporary lipid-lowering treatment pathways.
• Recognize consistent LDL-C reductions across diverse patient populations.
• Interpret efficacy alongside ongoing cardiovascular outcomes evaluation.
• Monitor emerging long-term effectiveness and implementation data.